Today's Market Winners and Losers

The stock market is mixed on Tuesday, with the Dow Jones Industrial Average down 0.01%, the Nasdaq up 0.21% and the S&P up 0.51%. Tuesday's winners include a telecommunications company who is near a deal with a larger firm and a pharmaceutical company whose drug received orphan status from the U.S. Food and Drug Administration. Meanwhile, the losers include another pharmaceutical company who discontinued a study on a lung-cancer drug and a retailer who cut its third-quarter outlook.

These are Tuesday's market winners and losers.

Biggest Winners

Shares of MetroPCS Communications Inc. (NYSE: PCS) are up 18.19% to $13.61 on trading volume of 6.7 million shares. Bloomberg reported Tuesday that Deutsche Telekom AG is near some sort of deal with MetroPCS. Before Tuesday, the 52-week high was $12.48.

Shares of Cell Therapeutics Inc. (NASDAQ: CTIC) are up 17.49% to $2.62 on trading volume of 4 million shares. The FDA granted orphan status to its brain cancer drug, the company announced Tuesday. The 52-week high is $8.25.

Biggest Losers

Shares of ArQule Inc. (NASDAQ: ARQL) are down 55.41% to $2.23 on trading volume of 16 million shares. The company said it is discontinuing its late-stage study of a drug for lung-cancer patients since it has shown it won't improve survival rates. Before Tuesday,  the 52-week low was $4.46.

Shares of Express Inc. (NYSE: EXPR) fell 20.45% to $11.94 on trading volume of 4.8 million shares. The company cut its third-quarter profit outlook to between 16 cents and 20 cents a share, down from 27 cents to 32 cents a share. Before Tuesday, the 52-week low was $14.50.

Samuel Weigley

Follow him on Twitter: SWeigley

Filed under: 24/7 Wall St. Wire, Market Roundups, Most Actives Tagged: ARQL, CTIC, EXPR, PCS
Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.